Inhaled nitric oxide options for neonatal pulmonary hypertension

Neonatal pulmonary hypertension describes persistent elevation of pulmonary vascular resistance after birth, often with right-to-left shunting through the ductus arteriosus or foramen ovale. It commonly appears as hypoxaemia that does not respond fully to ventilation, with differences between pre- and post-ductal oxygen saturation. Causes include meconium aspiration syndrome, congenital diaphragmatic hernia, sepsis, surfactant deficiency and idiopathic disease. Across Oceania, questions about neonatal pulmonary hypertension and inhaled nitric oxide alternatives must therefore cover both drug selection and the intensive-care capacity needed to use it. Learn more about 運動前のウォームアップが筋出力に与える影響.

Inhaled nitric oxide remains a standard selective pulmonary vasodilator in many tertiary neonatal units. By relaxing vascular smooth muscle in aerated lung, it can improve oxygenation and reduce right-to-left shunting without the systemic vasodilation associated with many older pulmonary vasodilators. Its effect depends on usable lung units, and it cannot replace treatment of the underlying condition. Response is variable, and a trial without benefit should prompt renewed assessment of lung recruitment, cardiac anatomy, pulmonary venous pressure and possible extracorporeal support rather than automatic escalation to another drug.

Australian and Pacific units also work under different constraints. Capital-city tertiary hospitals may have neonatal intensive care, paediatric cardiology and access to extracorporeal membrane oxygenation (ECMO) within one campus, while regional and Pacific services may have fewer staff, less reliable oxygen and long transfer times. The right question is not whether one drug is superior everywhere, but which combination can be started safely, monitored to effect and continued when a child moves between hospitals.

Why neonatal pulmonary hypertension remains difficult

The first challenge is identifying the disease rather than assuming every severe hypoxaemia is pulmonary hypertension. Echocardiography, oxygenation trends, blood pressure, lactate and response to lung recruitment help distinguish high pulmonary vascular resistance from cardiac, pulmonary venous or airway disease. A structured review also looks for meconium, infection, diaphragmatic hernia and persistent fetal circulation. This diagnostic discipline matters because vasodilators may help one physiology while worsening systemic hypotension or gas-exchange disturbance in another.

Even a well-selected patient may not respond to inhaled nitric oxide. Delivery depends on specialist equipment, trained staff, gas supply and monitoring for methaemoglobinaemia; many hospitals also face procurement and maintenance costs. Interrupted cylinder supply can interrupt a therapy that has already helped. Therefore, a medicine listed on a formulary is not the same as a reliable service, and contingency plans are as important as the initial prescription.

That broader need for shared evidence and resilient collaboration was reflected in the perinatal community represented by the FAOPS 2020 congress site. It documents the scientific programme and meeting information for the planned congress in Tokyo with PREBIC AA 2020, which was cancelled in April 2020 because of the COVID-19 pandemic and associated international travel difficulties. Its history underscores why regional knowledge sharing matters when individual centres cannot maintain every respiratory technology.

Comparing inhaled nitric oxide with alternatives

Alternatives should first be separated into substitutes for unavailable or contraindicated inhaled nitric oxide and adjuncts for an inadequate response. Sildenafil, a phosphodiesterase-5 inhibitor, is the most widely discussed oral option. It can reduce pulmonary vascular resistance and improve oxygenation in selected neonates, usually as off-label use and under specialist direction. Its effect is slower than that of inhaled nitric oxide, so it is not a substitute for immediate stabilisation. Hypotension, dose adjustment for renal function, drug interactions and the need for reliable oral or enteral administration must be considered.

Prostacyclin-pathway drugs provide a different balance. Intravenous epoprostenol has a rapid onset and may be valuable in severe disease, but it requires continuous preparation, vascular access and close blood-pressure monitoring. Inhaled iloprost or treprostinil can deliver pulmonary effects with less systemic exposure, although access, evidence and familiar paediatric formulations vary across Australia and the Pacific. Bosentan, a dual endothelin-receptor antagonist, may support longer-term management, with liver monitoring and limited neonatal experience.

Calcium-channel blockers such as nifedipine should not be used routinely for neonatal pulmonary hypertension; they have a role only when vasoreactivity testing identifies responsiveness, and they can cause systemic hypotension. Whichever option is chosen, teams should combine drug treatment with gentle ventilation, surfactant when indicated, correction of acidosis and circulatory dysfunction, and early ECMO referral for refractory hypoxaemia. A written escalation hierarchy is safer than relying on individual familiarity.

Delivering specialist care across Australia

Australian neonatal care is concentrated in major public tertiary units around Sydney, Melbourne, Brisbane, Perth and Adelaide. These hospitals usually bring neonatal intensive care, paediatric cardiology, imaging and ECMO expertise into the same network. Many private maternity hospitals manage routine deliveries, while babies requiring intensive therapy are commonly transferred to specialist public services. That split makes shared drug protocols, transport documentation and a single point of clinical contact essential.

State neonatal retrieval teams cover vast distances by road and aircraft, and clinicians may need to stabilise an infant long before a definitive echocardiogram or ECMO assessment. Secure teleconsultation can transmit observations and ultrasound images, but it works best when the referring team has a standard template covering oxygen delivery, ventilation, blood pressure, perfusion and vascular access. Written plans should state when to call a retrieval team, how medicines will be supplied in transit and which centre accepts the transfer.

After stabilisation, physiotherapy, handling and positioning support recovery, but the evidence base is much smaller than in rehabilitation for older children or athletes. A review of warm-up muscle findings from exercise research illustrates how preparation can affect muscle performance, yet it cannot be directly applied to neonatal treatment. The useful lesson is methodological: neonatal teams should use neonatal evidence, adjust activity to physiological readiness and avoid cold stress or handling that increases oxygen demand.

Adapting treatment for Pacific realities

Pacific neonatal services vary considerably. A facility in Fiji, Samoa, Tonga, Vanuatu or Papua New Guinea may have skilled neonatal staff but limited access to high-dependency beds, paediatric cardiology, blood products, reliable electricity or pipeline oxygen. Oxygen concentrators and cylinders can support care, yet they also compete with other hospital demand, while cyclone, flooding or aircraft disruption can delay transfer. A local plan must begin with available power, clean air, staff and medicines rather than a distant tertiary drug list.

Australasian support works best as a tiered system. A regional hub can review echocardiograms and vital signs in real time, help local clinicians titrate oxygen and support ventilation management, and coordinate a transfer before collapse. Common thresholds for escalation, medication concentrations and handover information reduce errors when families cross several health systems. The relationship should include nurses, biomedical engineers and pharmacists as well as doctors, since respiratory support fails when equipment or supplies do not match the written plan.

Equity also depends on who can reach the pathway. Remote Aboriginal and Torres Strait Islander families may face long journeys, disrupted services and a higher burden of respiratory illness, while Pacific families may need to travel across borders for tertiary care. Co-design with local communities, Aboriginal Community Controlled Health Services and Pacific health organisations can improve access and communication. The FAOPS perspective on resilient perinatal health systems supports this approach: reliable referral, flexible capacity and shared learning are core clinical infrastructure.

Using research and education to strengthen systems

Regulation and procurement shape what alternatives are genuinely available. The Therapeutic Goods Administration regulates products in the Australian market, but neonatal use may be off-label, requiring local approval, consent and documentation. Public hospitals manage inpatient medicines through formularies and supply contracts; Pharmaceutical Benefits Scheme arrangements for medicines used outside hospital should not be confused with inpatient access. Consequently, a tablet available through a metropolitan pharmacy may still be unavailable to a regional unit that lacks a suitable formulation, monitoring plan or named prescriber.

Local decisions should be supported by audit rather than anecdote. Networks can review indications for inhaled nitric oxide, time to treatment, echocardiographic reassessment, weaning, transfers to ECMO, adverse effects and mortality adjusted for illness severity. Standard definitions and regular feedback between referral and tertiary centres can reveal delays hidden by aggregate numbers. Research registries, university trial units and neonatal intensive-care data networks can add the denominator needed to compare pathways fairly.

Education has a similar role. A curated reading list might include Raskov clinical resources, local neonatal formularies, published neonatal trials and hospital protocols. The value of an external resource lies in prompting discussion, not replacing an up-to-date multidisciplinary standard. Teams should record the date, population and regulatory status of every recommendation, then adapt it to local nursing ratios, equipment and transfer times before introducing it into practice.

A practical pathway for coordinated action

A safe regional pathway begins with a short sequence: identify eligible infants, confirm pulmonary hypertension with echocardiography, stabilise the lung and circulation, start or continue inhaled nitric oxide when appropriate, and define when oral sildenafil, inhaled prostacyclin, intravenous epoprostenol or ECMO referral becomes relevant. Alternative medicines should have a defined place rather than appearing as unstructured rescue options. Monitoring should include blood pressure, perfusion, oxygenation, methaemoglobinaemia during nitric oxide treatment, renal function with relevant drugs and liver tests when endothelin antagonists are used.

Implementation requires named ownership. Each network should assign a clinical lead, pharmacist, nursing lead and retrieval coordinator. The formulary should separate medicines available at every admitting hospital, medicines held at referral centres and medicines requiring specialist authorisation. It should also cover concentration, administration, compatibility, observation duration, rescue options and what happens if supply fails. For off-label use, consent and review should be built into the order and handover process, with regular audit of exceptions and outcomes.

The immediate action is for Australian neonatal units and their Pacific partners to build one named regional pathway before the next respiratory crisis, appoint a 24-hour contact, map cylinder and medicine supply, and begin a shared audit of inhaled nitric oxide and alternative use. Conference delegates can carry the same discipline into education and policy: share protocols, publish response data and keep scientific exchange active even when international meetings cannot proceed. A named owner, a current formulary and an audited escalation plan will turn a collection of alternatives into a dependable treatment system.